Submissions from 2022
303 Maintenance of Repigmentation After Discontinuation of Ruxolitinib Cream in Patients With Vitiligo, David Rosmarin, Amit G. Pandya, Pearl Grimes, Mark G. Lebwohl, Alice B. Gottlieb, Iltefat Hamzavi, Kathleen Butler, and S. Wei
081 Modulation of the aryl hydrocarbon receptor by adipose tissue: Implications for skin carcinogenesis, S. Shareef, Jesse Veenstra, and J. J. Bernard
35180 “Could I be allergic to my new hidradenitis suppurativa Medication?” Characterization of a cutaneous delayed-type drug hypersensitivity reaction to secukinumab, Nayha Shetty, Sasank Konda, and Jesse Veenstra
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase III, randomized, double-blinded, placebo-controlled trials, Jonathan I. Silverberg, Diamant Thaçi, Julien Seneschal, Linda F. Stein Gold, Andrew Blauvelt, Eric Simpson, Chia-Yu Chu, Zhuqing T. Liu, Renata Gontijo Lima, Sreekumar Pillai, and Emma Guttman-Yassky
34587 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by anatomic region: Pooled analysis from two randomized phase 3 studies, Eric L. Simpson, Robert Bissonnette, and Linda F. Stein Gold
34039 Maintenance of skin clearance in a long-term open-label study of fixed-combination halobetasol propionate and tazarotene lotion for psoriasis in participants with prior use of topical treatments, Linda F. Stein Gold, Javier Alonso-Llamazares, and Joshua Zeichner
33463 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area, Linda F. Stein Gold, Jerry Bagel, James Del Rosso, Lawrence J. Green, Mark Lebwohl, Leon H. Kircik, Amy Feng, Scott Snyder, Robert C. Higham, Patrick Burnett, and David R. Berk
34613 Tapinarof cream 1% once daily (QD) for plaque psoriasis: Secondary efficacy outcomes from a long-term extension (LTE) trial, Linda F. Stein Gold, Benjamin Ehst, Laura K. Ferris, Philip M. Brown, David S. Rubenstein, Anna M. Tallman, and Jerry Bagel
33731 Use of digital resource centers for atopic dermatitis patients, caregivers, and health care professionals to improve shared decision-making and proactive management, Linda F. Stein Gold, Adam J. Friedman, and Kanwaljit Brar
Rapid and clinically meaningful improvement of plaque psoriasis-associated itch after treatment with calcipotriol and betamethasone dipropionate cream, Linda F. Stein Gold, Lawrence J. Green, Sunil Dhawan, Astrid Kirsch, Johan Selmer, and Morten Præstegaard
32970 Efficacy and safety of a fixed-dose clindamycin 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: Randomized phase 2 and phase 3 studies of the first triple-combination drug, Linda F. Stein Gold, Leon H. Kircik, and Emil A. Tanghetti
Improvement in psoriasis symptoms and involvement in special areas: 32-week results from advance, Linda F. Stein Gold, Kim Papp, David Pariser, Neal Bhatia, Howard Sofen, Lorne Albrecht, Melinda Gooderham, and Mindy Chen
Improvement in patient- and physician-reported outcomes with apremilast treatment in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial: Analyses by baseline BSA and PASI, Linda F. Stein Gold, Kim Papp, David Pariser, Lawrence Green, Neal Bhatia, Howard Sofen, Lorne Albrecht, and Melinda Gooderham
33354 Efficacy of apremilast in patients with mild to moderate psoriasis assessed by the physician global assessment and body surface area composite tool: Post hoc analysis from ADVANCE, Linda F. Stein Gold, Kim Papp, David Pariser, Howard Sofen, Mindy Chen, Sue Cheng, Hernan Picard, Yuri Klyachkin, and Lawrence Green
Impact of crisaborole in patients with mild-to-moderate atopic dermatitis who received prior treatment, Linda F. Stein Gold, Vivian Shi, Bonnie Vlahos, Paul Sanders, Chuanbo Zang, and Amy Cha
33356 A multinational chart review to examine gastrointestinal symptoms and their management in patients treated with apremilast for plaque psoriasis, Linda F. Stein Gold, Edward Tuttle, Wendy Y. Cheng, Rose Chang, Catherine Nguyen, Louise H. Yu, Anne Bouloc, Yuri Klyachkin, Tara Nazareth, and Denis Jullien
Tapinarof cream 1% once daily for plaque psoriasis: long-term extension trial of a novel therapeutic aryl hydrocarbon receptor modulating agent, Bruce Strober, Linda F. Stein Gold, Robert Bissonnette, April Armstrong, Andrew Blauvelt, Leon Kircik, Philip Brown, and Anna Tallman
359 Public sunscreen dispenser distribution in the United States: Continued COVID-19 trends during 2021, M. D. Szeto, R. Kokoska, Jalal Maghfour, C. Rundle, C. Presley, T. Harp, A. Hamp, V. Wegener, J. Hugh, and R. Dellavalle
33111 New onset scrotal lesions in a patient with herpes simplex virus treated with foscarnet, Rebecca F. Wang and Ben J. Friedman
34745 US and EU sunscreens: A review of ultraviolet (UV) filters and safety data, Nikita Wong, Milan N. Pantelic, and Michael Kwa
USE of OPTICAL COHERENCE TOMOGRAPHY and REFLECTANCE CONFOCAL MICROSCOPY to GUIDE TREATMENT MARGINS of BASAL CELL CARCINOMA, John Wuennenberg, David M. Ozog, Indermeet Kohli, and Brittani Jones
Proactive Management with Cal/BD Foam in Patients with Plaque Psoriasis prolongs Time with improved health-related Quality of Life when compared with reactive Management, Elisabeth Wurzer, Linda F. Stein Gold, Ahmad Jalili, Henrik Thoning, and Piergiacomo Calzavara-Pinton
ANALYSIS by OCT of PRE/POST LP 1064NM LASER TREATMENT of SUPERFICIAL and NODULAR BCCS, Christopher B. Zachary, John Soliman, Jon Holmes, David M. Ozog, John Wuennenberg, Wyatt Boothby-Shoemaker, Erica Baugh, and Indermeet Kohli
A randomized, double-blind, vehiclecontrolled Phase 2a study evaluating once daily roflumilast foam 0.3% in patients with moderate to severe seborrheic dermatitis, Matthew Zirwas, Zoe D. Draelos, Janet Dubois, Leon Kircik, Angela Y. Moore, Linda F. Stein Gold, Javier Alonso-Llamazares, and Michael Bukhalo
Submissions from 2021
A case of salivary gland hyalinizing clear cell carcinoma (HCCC) with cutaneous metastasis, Rand Abou Shaar, Sheeren Zia, Mohamed Alhamar, and Ben J. Friedman
A randomized, placebo-controlled, phase 2 study of the Janus Kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa, Afsaneh Alavi, Iltefat Hamzavi, Kurt Brown, Leandro L. Santos, Zhaoyin Zhu, Michael D. Howell, and Joslyn Kirby
27630 Assessing signs and symptoms of hidradenitis suppurativa from the patient perspective, aFSANEH Alavi, Iltefat H. Hamzavi, Sarah Baradaran, Susan D. Mathias, Hilary H. Colwell, Michael Song, and Chenglong Han
28353 Hemorrhagic cellulitis secondary to vibrio fluvialis infection, Harleen Arora and Chauncey A. McHargue
Correlation of PD-L1 expression, clinicopathologic and molecular characteristics in an array of solid tumors: A large-scale real world study, Kanika Arora, Harshita Mehrotra, Kasturi Saikia, Rand Abou Shaar, Mohamed Alhamar, and Dhananjay A. Chitale
Development and validation of facial vitiligo area scoring index (F-VASI) using the fingertip unit, Jung Min Bae, Raheel Zubair, Hyun Jeong Ju, Indermeet Kohli, Han Na Lee, S H. Eun, Alexis B. Lyons, Gautham Vellaichamy, Tae Young Han, Henry W. Lim, and Iltefat Hamzavi
PRO65 Engaging Patients in Drug Development for Regulatory and HTA Decisions: A Case Study in Patients with Hidradenitis Suppurativa, S Baradaran, S D. Mathias, H H. Colwell, A Alavi, Iltefat H. Hamzavi, M Song, R Villacorta, R Slowik, N Li, and C Han
26856 Proliferative nodule resembling angiomatoid Spitz with pronounced degenerative atypia arising within a giant congenital nevus, Taylor Braunberger, M Adelman, Tor Shwayder, L E. Clarke, and Ben J. Friedman
26843 Carbon dioxide laser excision for hidradenitis suppurativa patients—Healing, complications, and recurrence in patients with diabetes mellitus and history of smoking, Taylor Braunberger, P Vakharia, Nneamaka Ezekwe, Cynthia L. Nicholson, Angela Parks-Miller, and Iltefat H. Hamzavi
222 Whole-blood immune profile in hidradenitis suppurativa, Peter Dimitrion, Congcong Yin, Kalpana Subedi, Namir Khalasawi, Yi Yao, Angie Parks-Miller, Jesse Veenstra, Gautham Vellaichamy, Henry W. Lim, Iltefat Hamzavi, Li Zhou, and Qing-Sheng Mi
28043 Roflumilast cream significantly improves chronic plaque psoriasis in patients with steroid-sensitive area involvement, Zoe Draelos, Mark G. Lebwohl, Charles W. Lynde, Walter K. Nahm, Kim A. Papp, David M. Pariser, Linda F. Stein Gold, Daniel Stewart, Robert C. Higham, Lynn Navale, and David R. Berk
Roflumilast Cream Significantly Improves Chronic Plaque Psoriasis in Patients with Steroid-Sensitive Area Involvement, Zoe D. Drealos, Mark G. Lebwohl, Charles W. Lynde, Walter K. Nahm, Kim A. Papp, David Middle Pariser, Linda F. Stein Gold, and Daniel Stewart
26085 Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial, K C. Duffin, Linda F. Stein Gold, Craig Leonardi, David Pariser, Lawrence Green, Howard Sofen, Bruce Strober, Mindy Chen, Yao Wang, and Kim Papp
26914 Ustekinumab-induced myositis: A case series, Nneamaka Ezekwe, J Smith, Aunna Pourang, and Iltefat H. Hamzavi
Improvement in patient global impression measures with upadacitinib with or without topical corticosteroids in moderate to severe atopic dermatitis: Results from placebo-controlled phase 3 studies, M Gooderham, M Deleuran, Linda F. Stein Gold, B Calimlim, J Zeng, S Takemoto, E Raymundo, and S Weidinger
LB756 Patient-reported outcomes for sarecycline effectiveness in Acne Vulgaris in real-world settings: PROSES study protocol, E Graber, H Baldwin, J Harper, A Alexis, Linda F. Stein Gold, A Herbert, R Fried, E Rieder, L Kircik, J Del Rosso, I Kasujee, and A Grada
28666 Global initiatives in dermatology and education, C Grayson, Olabola Awosika, and E Pritchett
25486 Correlation of the Vitiligo Area Scoring Index with patient- and physician-reported measures of clinical improvement in a randomized, double-blind phase 2 study, Iltefat H. Hamzavi, David Rosmarin, Kathleen Butler, Fiona Kuo, Zhaoyin Zhu, and Kang Sun
A Diversity outbred (DO) mouse model reveals regulators of HER2-driven tumorigenesis, Jennifer Jacob, Kuang Wei, Joyce D. Reyes, Congcong Yin, Elizabeth Rondini, Qing-Sheng Mi, James Granneman, and Prahlad Parajuli
27099 Actinomyces infection within red pigment of a tattoo, Angela J. Jiang and Holly Kerr
28139 A case of IgA vasculitis associated with underlying cytomegalovirus colitis, Katelyn M. Kim and Ben J. Friedman
28367 A case of chronic prurigo nodularis, angiolymphoid hyperplasia with eosinophilia, and reactive lymphadenopathy: Intersection of multiple processes, or a novel clinical entity?, Elena Kurland, Bridget Myers, Ben J. Friedman, and Pranita V. Rambhatla
LB762 Initiation patterns among novel systemic agents for U.S. adults with Psoriasis and Psoriatic Arthritis, Michael Kwa, R Kang, M Cherupally, C Aikman, and R Ackermann
Roflumilast Cream, a Once-daily, Potent Phosphodiesterase-4 Inhibitor, in Chronic Plaque Psoriasis Patients: Efficacy and Safety from DERMIS-1 and DERMIS-2 Phase 3 Trials, Mark G. Lebwohl, Leon H. Kircik, Angela Y. Moore, Linda F. Stein Gold, Zoe D. Draelos, Melinda G. Gooderham, Kim A. Papp, and Jerry Bagel
Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: Results from the open-label run-in period of JADE REGIMEN, Mark G. Lebwohl, Margitta Worm, Linda F. Stein Gold, Christine Bangert, Peter Schmid-Grendelmeier, Tahira Khan, Pinaki Biswas, Marco DiBonaventura, Gary Chan, Ketti Terry, Hernan Valdez, and Claire Clibborn
28545 A man with halo nevi and premature hair graying, Alexis B. Lyons, Olabola Awosika, and Henry W. Lim
27636 Addition of narrow-band ultraviolet light B phototherapy to ruxolitinib cream in patients with vitiligo, Amit G. Pandya, John E. Harris, Mark Lebwohl, Iltefat H. Hamzavi, Kathleen Butler, Fiona Kuo, Shaoceng Wei, and David Rosmarin
25602 Improvements and response achievement in PASI subscale domains for head scaling and erythema in apremilast-treated patients with moderate to severe plaque psoriasis of the scalp: Results from the STYLE study, Kim Papp, Abby Van Voorhees, Linda F. Stein Gold, Mark Lebwohl, Bruce Strober, Zuoshun Zhang, and Yao Wang
26905 The effect of Polypodium leucotomos extract (Fernblock) on visible light and UV-induced photoaging, Aunna Pourang, Mohsen Dourra, Nneamaka Ezekwe, Indermeet Kohli, Iltefat Hamzavi, and Henry W. Lim
28522 The impact of the SARS-CoV-2 pandemic on phototherapy utilization, Aunna Pourang, Hailey Olds, Nneamaka Ezekwe, Henry W. Lim, and Iltefat H. Hamzavi
28206 Disseminated gonococcal infection manifesting as embolic septic vasculitis, Vignesh Ramachandran and Sasank Konda
28714 Primary cutaneous Fusarium infection in an immunocompetent host, Gabrielle Robinson, Ben J. Friedman, and Chauncey A. McHargue
27568 Maintenance of repigmentation after discontinuation of ruxolitinib cream in patients with vitiligo, David Rosmarin, Amit G. Pandya, Pearl Grimes, Mark Lebwohl, Alice B. Gottlieb, Iltefat H. Hamzavi, Kathleen Butler, Fiona Kuo, Shaoceng Wei, Beth Rumberger, and John E. Harris
27426 A young man with an impressive ulcer on the chest, Ethan Sagher and Anna Axelson
27874 Correlation of itch response to roflumilast cream with disease severity and patient-reported outcomes in patients with chronic plaque psoriasis, Linda F. Stein Gold, Javier Alonso-Llamazares, Zoe D. Draelos, Melinda J. Gooderham, Steven E. Kempers, Mark G. Lebwohl, Darryl P. Toth, Gil Yosipovitch, Robert C. Higham, Lynn Navale, and David R. Berk
Correlation of Itch Response to Roflumilast Cream with Disease Severity and Patient-Reported Outcomes in Patients with Chronic Plaque Psoriasis, Linda F. Stein Gold, Javier Alonso-Llamazares, Zoe D. Drealos, Melinda J. Gooderham, Steven E. Kempers, Mark G. Lebwohl, Darryl P. Toth, and Gil Yosipovitch
25750 Tapinarof cream 1% once daily for plaque psoriasis: Secondary efficacy outcomes from two pivotal phase 3 trials, Linda F. Stein Gold, Andrew Blauvelt, April Armstrong, Seemal R. Desai, Howard Sofen, Lawrence J. Green, Stephen K. Tyring, Laura K. Ferris, Philip M. Brown, David S. Rubenstein, and Stephen C. Piscitelli
Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients with Chronic Plaque Psoriasis: Results from a 52-Week, Phase 2b Open-Label Study, Linda F. Stein Gold, Melinda J. Gooderham, Kim A. Papp, Laura K. Ferris, Mark G. Lebwohl, David N. Adam, Javier Alonso-Llamazares, and H. Chih-ho Hong
26607 Proactive management using Cal/BD foam in patients with plaque psoriasis prolongs time with a health-related quality of life improvement, compared with reactive management, Linda F. Stein Gold, Ahmad Jalili, Dominique Lons Danic, Nanna Nyholm, Henrik Thoning, and Piergiacomo Calzavara-Pinton
27611 Fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion for the treatment of plaque psoriasis in patients with 3-5% body surface area (BSA) and poor quality of life (QoL), Linda F. Stein Gold, Edward Lain, Jerry Bagel, and Abby Jacobson
Proactive Management with Twice-Weekly Topical Cal/BD Foam Prolongs Treatment Efficacy Versus Reactive Management in Patients with Plaque Psoriasis, Linda F. Stein Gold, Charles Lynde, Javier Alonso-Llamazares, Philip Laws, Paul Yamauchi, Henrik Thoning, Camilla Toxvaerd, and Michael Sticherling
Efficacy and Safety of Apremilast in Patients with Mild to Moderate Psoriasis: Results from the 16- Week, Double-Blind Phase of the ADVANCE Trial, Linda F. Stein Gold, Kim Papp, Craig Leonardi, David Pariser, Lawrence Green, Neal Bhatia, Howard Sofen, and Lorne Albrecht
Crisaborole ointment, 2%, in patients 3 months of age and older with mild-to-moderate atopic dermatitis (AD), J C. Su, L J. Spelman, L F. Eichenfield, Linda F. Stein Gold, A Cha, D Graham, L Takiya, J L. Werth, C Zang, and B Vlahos
25603 Improvement in scalp psoriasis and quality of life with apremilast in patients with moderate to severe scalp psoriasis regardless of prior systemic treatment: Results from the phase 3, randomized STYLE study, Yao Wang, Linda F. Stein Gold, Mark Lebwohl, Bruce Strober, Zuoshun Zhang, and Abby Van Voorhees
28588 Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a randomized, double-blind, vehicle-controlled phase 2 study, Matthew Zirwas, Zoe D. Draelos, Janet DuBois, Leon Kircik, Angela Moore, Linda F. Stein Gold, Robert C. Higham, Lynn Navale, Patrick Burnett, and David R. Berk
Efficacy and Safety of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a Randomized, Double-blind, Vehicle-controlled Phase 2 Study, Matthew Zirwas, Zoe D. Draelos, Janet Dubois, Leon Kircik, Angela Y. Moore, Linda F. Stein Gold, Robert C. Higham, and Lynn Navale
Submissions from 2020
16392 Efficacy of tapinarof cream by body region in subjects with plaque psoriasis in a phase 2b randomized controlled study, R Bissonnette, Linda F. Stein Gold, L Kircik, S K. Tyring, A Tallman, and A Armstrong
15821 Efficacy and safety of carbon dioxide laser excision in hidradenitis suppurativa: Experience from an urban academic medical center, Taylor Braunberger, P Vakharia, Shanthi Narla, C Nicholson, and Ashley Parks-Miller
LB938 Efficacy of FMX101 4% topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Integrated summary from three phase 3 studies, J Del Rosso, Linda F. Stein Gold, J Weiss, L Green, V Stakias, and I Stuart
16520 Continuing medical education on acne improves dermatologists’ knowledge and competence on patient management, S J. Dermer, J M. Maeglin, and Linda F. Stein Gold
17753 Analysis of 24-week response to ruxolitinib cream for the treatment of vitiligo based on patient demographics and clinical characteristics, Iltefat Hamzavi, J E. Harris, D Rosmarin, P E. Grimes, A Pandya, A B. Gottlieb, K A. Butler, I FI Kuo, K Sun, and M Lebwohl
17955 Comparison of SPF50+ and SPF100+ sunscreens on the induction of cutaneous pigmentation over multiple days: A real-world, single-center, randomized, double-blinded evaluation, Indermeet Kohli, C Nicholson, J D. Williams, I Seo, X Tian, E Atillasoy, Henry W. Lim, and Iltefat H. Hamzavi
The infection rate of intralesional triamcinolone and the safety of compounding in dermatology for intradermal and subcutaneous injection: A retrospective medical record review, Chelsea A. Luther, James L. Griffith, Elena Kurland, Reem Al Shabeeb, Misty Eleryan, Kelley Redbord, and David M. Ozog
15485 Evaluating the safety and efficacy of intense pulsed light with radiofrequency in US patients with hidradenitis suppurativa: A split-body study, Alexis B. Lyons, Raheel Zubair, Angela Parks-Miller, Indermeet Kohli, and Iltefat H. Hamzavi
13303 Prevalence of photodermatoses in the general dermatology clinic of four academic medical centers: A multicenter retrospective analysis of 1080 patients over a 10-year period, Tasneem F. Mohammad, R Hamel, A Chahine, G L. Vick, E Boh, M BT Alora, R Mistur, E D. Baron, K Cooper, and Henry W. Lim
15838 Autoimmune comorbidities of psoriasis in US adults and children, Shanthi Narla and J I. Silverberg
18303 Ataxia telangiectasia and melanoma: The role of dermatology in ataxia telangiectasia, S Oska, Danielle Yeager, Allison Zarbo, Ben J. Friedman, and Tor Shwayder
13882 Trifarotene 50 μg/g cream: An effective and safe treatment for moderate facial and truncal acne, J D. Rosso, J Tan, J S. Weiss, Linda F. Stein Gold, F Cook-Bolden, L Eichenfield, E Tanghetti, M Graeber, A A. Saenz, and F Ahmad
Impact of Gender and Race on Outcomes of Patients Treated for Mycosis Fungoides with Total Skin Electron Beam Therapy, Eric Schaff, David Bergman, Charlotte Burmeister, Chauncey A. McHargue, Henry W. Lim, and Farzan Siddiqui
13509 Integrated safety analysis of FMX103 1.5% topical minocycline foam for the treatment of moderate to severe papulopustular rosacea: Results from two phase 3 studies, Linda F. Stein Gold, J Q. Del Rosso, L Kircik, N Bhatia, D Hooper, and W K. Nahm
17800 Open-label extension study evaluating the long-term safety, efficacy, and tolerability of FMX103 1.5% topical minocycline foam in the treatment of moderate to severe facial papulopustular rosacea, Linda F. Stein Gold, J Q. Del Rosso, L Kircik, N Bhatia, D Hooper, W K. Nahm, and I Stuart
605 Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion, Linda F. Stein Gold, M G. Lebwohl, N Bhatia, T Lin, and R Pillai
15324 Long-term management of moderate to severe plaque psoriasis: Maintenance of treatment success following cessation of fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in patients with baseline body surface area of 6%-12%, Linda F. Stein Gold, J S. Weiss, L J. Green, L Kircik, T L. PharMd, and S Harris
513 Crisaborole in patients ≥3 months of age with mild-to-moderate atopic dermatitis (AD), J C. Su, L J. Spelman, L F. Eichenfield, and Linda F. Stein Gold
17754 Treatment success in mild psoriasis patients with fixed-combination calcipotriene and betamethasone dipropionate foam: Results from the PSO-FAST trial, K A. Veverka, J B. Hansen, M Yaloumis, L Kircik, and Linda F. Stein Gold
Using patient education to achieve optimal results with their topical retinoid/benzoyl peroxide therapy, Colleen Vlachos and Jessica M. Hutchings
350 Histone demethylase LSD1 is required for LC embryonic development but dispensable for LC maintenance and repopulation, Xuan Wang, Yi Yao, Y Wang, Li Zhou, and Qing-Sheng Mi
15211 Treatment of moderate to severe acne with once-daily tazarotene 0.045% lotion in males: Pooled analysis of two phase 3 studies, J S. Weiss, N Bhatia, Linda F. Stein Gold, G Martin, R Pillai, and E Guenin
15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial, G Yosipovitch, T Bieber, Linda F. Stein Gold, S Kwatra, S Tatulych, C Nduaka, M C. Cameron, D Williams, P Biswas, and H Valdez
360 CBFβ2 is required for LC hemostasis and repopulation but not required for its embryonic development, Qian Yu, Li Zhou, and Qing-Sheng Mi
18618 A differential diagnosis for the congenital midline mass: Striated muscle hamartoma, Allison Zarbo, Kevin M. Luk, Ben J. Friedman, and Tor Shwayder
Submissions from 2019
Impact of Race and Gender on Outcomes for Total Skin Electron Beam Therapy in Mycosis Fungoides, David Bergman, Charlotte Burmeister, Chauncey McHargue, Henry W. Lim, and Farzan Siddiqui
TGFβ/Smad2/4 Signaling Pathway Is Required for Epidermal Langerhans Cell Repopulation Under Inflammation Condition but Not for Their Homeostasis, Maturation and Migration in the Steady State, Steven Cvetkovski, L Huang, G Li, X Yu, I Udo-Inyang, Congcong Yin, Li Zhou, Z Yao, and Qing-Sheng Mi
Pediatric pigmented epithelioid melanocytoma of the scalp with NKTR3 gene rearrangement, Ben J. Friedman and Angela J. Jiang
Transcriptomic profiling of tumor infiltrating cells in cutaneous squamous cell carcinoma using single-cell rna sequencing, James Glassbrook, Hongmei Peng, Yi Yao, X Wu, Li Zhou, and Qing-Sheng Mi
Rapid and effective itch relief using calcipotriol plus betamethasone dipropionate foam in patients with psoriasis, A Jalili, M Lebwohl, Linda F. Stein Gold, S B. Andersen, K L. Jensen, and D Thaci
